Abbisko Therapeutics Reports Positive Phase 2 Lavengratinib Data
Shanghai, China, September 21, 2026 Abbisko Therapeutics has announced positive preliminary results from a Phase 2 clinical study evaluating...
achondroplasia
Advertisement
BridgeBio Advances Oral Infigratinib Toward Achondroplasia Launch
PALO ALTO, Calif. — September 9, 2026 BridgeBio Pharma, Inc. presented new exploratory analyses from the Phase 3 PROPEL...
AstraZeneca Tagrisso Combo Improves Lung Cancer PFS
Cambridge, UK, September 1, 2026 AstraZeneca has announced positive high-level results from the Phase III SANOVO trial, showing that...
Ascendis, BioMarin Reach Global YUVIWEL License Deal
COPENHAGEN, Denmark, August 31, 2026 Ascendis Pharma A/S and BioMarin Pharmaceutical Inc. have entered into a binding term sheet...
Ascendis Pharma Shows Positive Long-Term COACH Results
COPENHAGEN, Denmark, August 6, 2026 Ascendis Pharma A/S announced encouraging updates across its achondroplasia development programs, highlighting positive Week...
Advertisements
BioMarin FDA Accepts VOXZOGO sNDA for Full Approval
SAN RAFAEL, Calif., July 13, 2026 BioMarin Pharmaceutical Inc. has reached a significant regulatory milestone after the U.S. Food...
BridgeBio Reports Positive Phase 3 Oral Infigratinib Results for Achondroplasia
PALO ALTO, Calif., June 28, 2026 BridgeBio Pharma announced that positive results from its pivotal Phase 3 PROPEL 3...
BioMarin Reports Positive VOXZOGO and BMN 333 Data at ENDO 2026
SAN RAFAEL, Calif., June 16, 2026 BioMarin Pharmaceutical Inc. announced new clinical findings from its approved therapy VOXZOGO® (vosoritide)...
BioMarin Reports Positive Phase 3 VOXZOGO Data in Hypochondroplasia
SAN RAFAEL, Calif., May 20, 2026 BioMarin Pharmaceutical Inc. announced positive topline results from the pivotal Phase 3 CANOPY-HCH-3...
Advertisement
